特应性皮炎的全球健康视角
国际特应性皮炎学会在2023年世界皮肤病学大会新加坡圆桌会议上讨论了AD全球负担。专家组认为现有指南不适用于低资源地区,建议优先预防研究,并强调基层医疗管理AD及其共病。
要点
- 1990至2019年AD年龄标化患病率和发病率相对稳定。
- 现有AD指南不适用于低资源地区,需更务实方法。
核心结论
- 当前AD指南不适用于低资源地区,需采用更务实方法。
- 应优先开展预防研究,不论现有资源水平。
- 优化AD及其共病管理需加强基层医疗。
研究设计与样本
- 国际特应性皮炎学会在2023年世界皮肤病学大会新加坡圆桌会议组织讨论。
- 比较世界银行类别1、3和4国家的经验。
主要发现
- 1990至2019年AD年龄标化患病率和发病率相对稳定。
- 多数AD病例为轻至中度。
- 缺乏疾病患病率和严重度平行数据,GBD数据在许多地区难以解读。
- 间接证据提示低中等资源地区AD负担显著,尤其是城市地区。
临床怎么用
- 低资源地区可参考WHO针对皮肤被忽视热带病的更务实方法。
- 世界银行类别3和大多数类别4国家轻中度AD主要问题是就诊时间不足导致依从性差,而非药物可及性。
- 与WHO、患者倡导组织和行业合作可促进全球变革、改善能力培训并应对不平等。
- 在基层医疗层面优化AD及其共病管理,因为多数环境下专科诊疗难以企及。
- 未来目标包括基层医疗赋能、存储转发远程医疗和基于增强智能的算法。
局限性
- 缺乏疾病患病率和严重度平行数据,GBD数据在许多地区难以解读。
- 低中等资源地区证据为间接证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The International Society of AD (ISAD) organized a roundtable on global aspects of AD at the WCD 2023 in Singapore. According to the Global Burden of Disease (GBD) consortium, at least 171 million individuals were affected with AD in 2019, corresponding to 2.23% of the world population, with age-standardized prevalence and incidence rates that were relatively stable from 1990 to 2019. Based on the panel experience, most AD cases are mild-to-moderate. Without parallel data on disease prevalence and severity, the GBD data are difficult to interpret in many regions. This gap is particularly important in countries with limited medical infrastructure, but indirect evidence suggests a significant burden of AD in low-and-medium resource settings, especially urban areas. The Singapore roundtable was an opportunity to compare experiences in World Bank category 1 (Madagascar and Mali), 3 (Brazil, China) and 4 (Australia, Germany, Qatar, USA, Singapore, Japan) countries. The panel concluded that current AD guidelines are not adapted for low resource settings and a more pragmatic approach, as developed by WHO for skin NTDs, would be advisable for minimal access to moisturizers and topical corticosteroids. The panel also recommended prioritizing prevention studies, regardless of the level of existing resources. For disease long-term control in World Bank category 3 and most category 4 countries, the main problem is not access to drugs for most mild-to-moderate cases, but rather poor compliance due to insufficient time at visits. Collaboration with WHO, patient advocacy groups and industry may promote global change, improve capacity training and fight current inequalities. Finally, optimizing management of AD and its comorbidities needs more action at the primary care level, because reaching specialist care is merely aspirational in most settings. Primary care empowerment with store and forward telemedicine and algorithms based on augmented intelligence is a future goal.
引用
- Faye O, Flohr C, Kabashima K, et al. Atopic dermatitis: A global health perspective. J Eur Acad Dermatol Venereol. 2023. PMID: 38151270. doi:10.1111/jdv.19723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。